Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare and Social Assistance

>>

Asia Pacific Small Molecule API Market


Asia Pacific Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity

Report code: SDMRHE1580779 | Industry: Healthcare and Social Assistance | Published On: 44314


Asia Pacific small molecule active pharmaceutical ingredient (API) market will grow by 9.2% annually with a total addressable market cap of $537.3 billion over 2021-2027 owing to increasing incidences of diseases, development of companies engaged in the manufacturing of small molecule APIs, the increasing technological developments in manufacturing sector, and surge in healthcare expenditure amid COVID-19 pandemic.
Highlighted with 33 tables and 52 figures, this 112-page report “Asia Pacific Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific small molecule API market in every aspect of the classification from perspectives of Source, Type, Therapeutic Area, Application, Manufacturer Type, and Country.

Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Semi-synthetic API
• Natural Origin

Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
• Standard API
• High Potency API (HPAPI)
o Branded HPAPI
o Generic HPAPI

Based on Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Applications

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
o Clinical Use
o Commercial Use

Based on Manufacturer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
• Pharmaceutical Companies
• CMOs

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2017-2027. The breakdown of key national markets by Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent, Inc.
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction 7
1.1  Industry  Definition  and  Research  Scope 7
1.1.1  Industry  Definition 7
1.1.2  Research  Scope 8
1.2  Research  Methodology 11
1.2.1  Overview  of  Market  Research  Methodology 11
1.2.2  Market  Assumption 12
1.2.3  Secondary  Data 12
1.2.4  Primary  Data 12
1.2.5  Data  Filtration  and  Model  Design 14
1.2.6  Market  Size/Share  Estimation 15
1.2.7  Research  Limitations 16
1.3  Executive  Summary 17
2  Market  Overview  and  Dynamics 20
2.1  Market  Size  and  Forecast 20
2.1.1  Impact  of  COVID-19  on  World  Economy 21
2.1.2  Impact  of  COVID-19  on  the  Market 23
2.2  Major  Growth  Drivers 25
2.3  Market  Restraints  and  Challenges 28
2.4  Emerging  Opportunities  and  Market  Trends 31
2.5  Porter’s  Fiver  Forces  Analysis 35
3  Segmentation  of  Asia  Pacific  Market  by  Source 39
3.1  Market  Overview  by  Source 39
3.2  Synthetic  API 41
3.2.1  Branded  Synthetic  API 42
3.2.2  Generic  Synthetic  API 43
3.3  Semi-synthetic  API 44
3.4  Natural  Origin 45
4  Segmentation  of  Asia  Pacific  Market  by  Type 46
4.1  Market  Overview  by  Type 46
4.2  Standard  API 48
4.3  High  Potency  API  (HPAPI) 49
4.3.1  Branded  HPAPI 50
4.3.2  Generic  HPAPI 51
5  Segmentation  of  Asia  Pacific  Market  by  Therapeutic  Area 52
5.1  Market  Overview  by  Therapeutic  Area 52
5.2  Infectious  Diseases 54
5.3  Oncology 55
5.4  Ophthalmology 56
5.5  Cardiovascular  Disorders 57
5.6  Central  Nervous  System 58
5.7  Respiratory  Disorders 59
5.8  Metabolic  Diseases 60
5.9  Other  Applications 61
6  Segmentation  of  Asia  Pacific  Market  by  Application 62
6.1  Market  Overview  by  Application 62
6.2  Clinical  Use 64
6.3  Commercial  Use 65
7  Segmentation  of  Asia  Pacific  Market  by  Manufacturer  Type 66
7.1  Market  Overview  by  Manufacturer  Type 66
7.2  Pharmaceutical  Companies 68
7.3  CMOs 70
8  Asia-Pacific  Market  2020-2027  by  Country 72
8.1  Overview  of  Asia-Pacific  Market 72
8.2  China 75
8.3  Japan 77
8.4  India 80
8.5  Australia 82
8.6  South  Korea 84
8.7  Rest  of  APAC  Region 86
9  Competitive  Landscape 88
9.1  Overview  of  Key  Vendors 88
9.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 91
9.3  Company  Profiles 92
Aurobindo  Pharma  Ltd. 92
Cambrex  Corporation 94
Catalent,  Inc. 95
Dr.  Reddy's  Laboratories  Ltd. 96
GlaxoSmithKline  plc 97
Lonza  Group 98
Merck  &  Co.,  Inc. 99
Mylan  N.V. 100
Novartis  AG 101
Pfizer  Inc. 102
Sun  Pharmaceutical  Industries  Ltd. 103
Teva  Pharmaceutical  Industries  Ltd. 104
Wuxi  AppTec  Co.,  Ltd. 105
10  Investing  in  Asia  Pacific  Market:  Risk  Assessment  and  Management 106
10.1  Risk  Evaluation  of  Asia  Pacific  Market 106
10.2  Critical  Success  Factors  (CSFs) 109
Related  Reports  and  Products 112
Table 1. Snapshot of Asia Pacific Small Molecule API Market in Balanced Perspective, 2020-2027 18
Table 2. Growth Rate of World GDP, 2020-2022 22
Table 3. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule API Market 31
Table 4. Asia Pacific Small Molecule API Market by Source, 2017-2027, $ mn 39
Table 5. Asia Pacific Small Molecule API Market: Synthetic API by Drug Type, 2017-2027, $ mn 41
Table 6. Asia Pacific Small Molecule API Market by Type, 2017-2027, $ mn 46
Table 7. Asia Pacific Small Molecule API Market: HPAPI by Drug Type, 2017-2027, $ mn 49
Table 8. Asia Pacific Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 52
Table 9. Asia Pacific Small Molecule API Market by Application, 2017-2027, $ mn 62
Table 10. Asia Pacific Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 66
Table 11. APAC Small Molecule API Market by Country, 2017-2027, $ mn 73
Table 12. China Small Molecule API Market by Type, 2017-2027, $ mn 76
Table 13. China Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 76
Table 14. China Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 76
Table 15. Japan Small Molecule API Market by Type, 2017-2027, $ mn 79
Table 16. Japan Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 79
Table 17. Japan Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 79
Table 18. India Small Molecule API Market by Type, 2017-2027, $ mn 81
Table 19. India Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 81
Table 20. India Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 81
Table 21. Australia Small Molecule API Market by Type, 2017-2027, $ mn 83
Table 22. Australia Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 83
Table 23. Australia Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 83
Table 24. South Korea Small Molecule API Market by Type, 2017-2027, $ mn 85
Table 25. South Korea Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 85
Table 26. South Korea Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 85
Table 27. Small Molecule API Market in Rest of APAC by Country/Region, 2017-2027, $ mn 87
Table 28. Aurobindo Pharma Ltd.: Company Snapshot 92
Table 29. Aurobindo Pharma Ltd.: Business Segmentation 92
Table 30. Aurobindo Pharma Ltd.: Product Portfolio 93
Table 31. Aurobindo Pharma Ltd.: Revenue, 2017-2019, $ mn 93
Table 32. Risk Evaluation for Investing in Asia Pacific Market, 2020-2027 107
Table 33. Critical Success Factors and Key Takeaways 110
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT